Given its aberrant expression in diverse cancers and its influence on critical cell functions, PCAT-1 presents as a potential therapeutic target for CRC, particularly for controlling inflammation and modulating tumor–stroma immune interactions [125,126]. The gene discussed is PCAT1; the disease is cancer.